New data revealing the potential for Kempharm Inc.'s hydrocodone prodrug, KP-201 (benzhydrocodone), to deter abuse by yielding lower hydrocodone exposure when snorted vs. generic hydrocodone bitartrate moved the company closer to what it expects will be a fourth quarter FDA NDA filing.